Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xenogen Corporation

Request full access

An integrated system of instruments and equipment, software and reagents to academic and biopharmaceutical spheres

Oakland, United StatesBiotech & Life Sciences

About Xenogen Corporation

Xenogen Corporation, founded in 1995 by Pamela Contag, Ph.D., and David Benaron, positioned itself as a biotechnology firm focused on expediting the drug discovery and development process. The company's core offering was an integrated suite of biophotonic, real-time in vivo imaging and genetic modification technologies. This technology was born from Dr. Contag's post-doctoral work at Stanford University, where she and her colleagues invented in vivo biophotonic imaging. Her background in microbiology and genetics at the University of Minnesota Medical School provided a strong foundation for this venture.

Xenogen's business model revolved around providing tools and services to the pharmaceutical and biotechnology sectors. The company's flagship product line, the VivoVision™ Systems, enabled researchers to non-invasively illuminate and monitor biological processes within living mammals at the molecular level and in real time. This capability offered the significant benefit of yielding higher quality in vivo data earlier in the drug discovery pipeline, which could substantially reduce the time and cost associated with bringing new therapies to market. In addition to its imaging systems, Xenogen provided services in creating and characterizing animal models through its Xenogen Biosciences division. This included genetic modifications like gene knockouts and knock-ins, as well as comprehensive phenotyping and compound profiling.

The company's technology facilitated non-invasive, longitudinal monitoring of disease progression, cell trafficking, and gene expression patterns in living animals, providing crucial insights for preclinical research across multiple therapeutic areas. By making biological processes visible, Xenogen's tools assisted researchers in evaluating drug targets and compounds more effectively. The company showed strong revenue growth, increasing from \$20.1 million in 2003 to \$30.8 million in 2004. Following a public offering in 2004, Xenogen Corporation was acquired by Caliper Life Sciences in February 2006 for approximately \$80 million. This merger was a strategic move to combine Caliper's expertise in microfluidics and automation with Xenogen's in vivo imaging technology, aiming to bridge the gap between in vitro and in vivo research.

Source: Dealroom company data

Xenogen Corporation in the Oakland ecosystem

Live from Dealroom

The Xenogen Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

  • SR One
  • Delphi Ventures
  • Charlesbank Capital Partners
  • Abingworth
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Oakland HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xenogen Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xenogen Corporation on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.